We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
DIACOMIT (Emerge Health Pty Ltd)
Product name
DIACOMIT
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
242 working days (255)
Active ingredients
stiripentol
Registration type
NCE/NBE
Indication
DIACOMIT (capsule/powder for oral suspension) is indicated for adjunctive treatment of generalised tonic-clonic and clonic seizures associated with severe myoclonic epilepsy in infancy (SMEI, also known as Dravet syndrome) in patients whose seizures are not adequately controlled with a benzodiazepine (usually clobazam) and valproate.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.